Volume 16, Number 7—July 2010
ACC-1 β-Lactamase–producing Salmonella enterica Serovar Typhi, India
To the Editor: Typhoid fever, caused by Salmonella enterica serovar Typhi, is a serious form of enteric fever. In 2000, the worldwide number of typhoid cases was estimated to be >21,000,000, and there were >200,000 deaths from this disease (1).
Ciprofloxacin is the first-line drug of choice for treatment of patients with typhoid fever, but there has been an increase in strains resistant to ciprofloxacin (2) and resistance to third-generation cephalosporins has emerged (3). There are sporadic reports of high resistance to ceftriaxone in typhoidal salmonellae (3,4) in which CTX-M-15 and SHV-12 extended spectrum β-lactamases (ESBLs) have been reported. To date, there are no reports of AmpC β-lactamases in typhoidal salmonellae. AmpC β-lactamases confer resistance to a broad spectrum of β-lactams, which greatly limits therapeutic options. We investigated an isolate of S. Typhi by using serotyping, antimicrobial drug susceptibility testing, PCR screening for β–lactamase genes, and sequence analysis to confirm the identity of the isolate and the β–lactamase gene involved in conferring resistance to this isolate.
The isolate was obtained in Bangalore, India, in August 2009, from the blood of a female patient (14 years of age) who was hospitalized because of signs and symptoms of enteric fever. She had no history of having received antimicrobial drugs. After a blood sample was cultured, the patient was empirically treated with ceftriaxone but did not clinically improve.
Culture yielded gram-negative bacteria after 48 hours. The isolate was identified by standard biochemical methods as S. Typhi. Identification was confirmed by using Salmonella spp. polyvalent O, O9, and H:d antisera (Murex Biotech, Dartford, UK). Susceptibility to antimicrobial drugs was assessed by using the Kirby-Bauer disk diffusion method according to Clinical and Laboratory Standards Institute guidelines (www.clsi.org). The isolate was resistant to ampicillin, piperacillin, cefoxitin, cefotaxime, ceftazidime, ceftriaxone, aztreonam, amoxicillin/clavulanate, and cefepime. It was susceptible to chloramphenicol, trimethoprim/sulfamethoxazole, nalidixic acid, ciprofloxacin, and meropenem.
Treatment was changed to ciprofloxacin (500 mg every 12 h for 7 d). The patient recovered within 72 hours and was discharged. MICs were determined for ciprofloxacin, gatifloxacin, ofloxacin, ceftazidime, ceftriaxone, and amoxicillin/clavulanate by using the Etest (AB Biodisk, Solna, Sweden) (Table). MIC for ceftriaxone was confirmed by an agar dilution method (www.clsi.org). The isolate was tested for ESBLs by using a method with disks containing ceftazidime (30 μg) and ceftazidime/clavulanate (30 μg/10 μg). The AmpC disk test for detection of plasmid-mediated AmpC β-lactamase was conducted according to standard methods (5).
PCR screening and sequencing was performed to identify β-lactamase resistance genes blaTEM, blaSHV, blaOXA-1 group, blaCTX-M, and AmpC as described (6,7). Sequencing of β-lactamase gene amplicons was conducted at the Vector Control Research Centre in Pondicherry, India. The BLASTN program (www.ncbi.nlm.nih.gov/BLAST) was used for database searching. We also used a nested PCR specific for the flagellin gene of S. Typhi to confirm identity of the isolate (8). The nested PCR amplicon was sequenced to confirm identity of the flagellin (fliC) gene of S. Typhi. Sequencing of the flagellin gene product was conducted by Cistron Bioscience (Chennai, India).
The isolate was negative for ESBL production. PCR amplification and sequencing showed that the isolate harbored blaTEM-1 and blaACC-1. The isolate was negative by PCR for other β-lactamases tested. TEM-1 is one of the most commonly encountered β-lactamases in the family Enterobacteriaceae and can hydrolyze narrow-spectrum penicillins and cephalosporins.
We report ACC-1 AmpC β-lactamase in typhoidal salmonellae. S. Typhi could have acquired the AmpC β- lactamase from drug-resistant bowel flora. After the isolate was found to be highly resistant to ceftriaxone, the change in therapy to ciprofloxacin helped in recovery of the patient without any sequelae.
ACC-1 AmpC β-lactamases originated in Hafnia alvei and are now found in various members of the family Enterobacteriaceae (9). The ACC-1 AmpC β-lactamases are exceptional in that they do not confer resistance to cephamycins (10). Our isolate contained blaTEM-1 and blaACC-1 and was resistant to cefoxitin and cefepime but susceptible to meropenem. Bidet et al. (9) reported isolating Klebsiella pneumoniae resistant to cefoxitin and cefepime and intermediate resistance to imipenem. Atypical resistance was attributed to ACC-1 β-lactamase production and loss of a 36-kDa major outer membrane protein (9). We did not analyze changes in the outer membrane proteins responsible for alteration of permeability.
Continual monitoring of drug resistance patterns is imperative. Antimicrobial drug susceptibility testing should be conducted for clinical isolates, and empirical antimicrobial drug therapy should be changed accordingly. AmpC β-lactamase genes will eventually be transferred to typhoidal salmonellae, which may pose a threat to public health. Spread of broad-spectrum β-lactamases would greatly limit therapeutic options and leave only carbapenems and tigecycline as secondary antimicrobial drugs.
- Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346–53.
- Harish BN, Menezes GA, Sarangapani K, Parija SC. A case report and review of the literature: ciprofloxacin resistant Salmonella enterica serovar Typhi in India. J Infect Dev Ctries. 2008;2:324–7.
- Al Naiemi N, Zwart B, Rijnsburger MC, Roosendaal R, Debets-Ossenkopp YJ, Mulder JA, Extended-spectrum-beta-lactamase production in a Salmonella enterica serotype Typhi strain from the Philippines. J Clin Microbiol. 2008;46:2794–5.
- Rotimi VO, Jamal W, Pal T, Sovenned A, Albert MJ. Emergence of CTX-M-15 type extended-spectrum β-lactamase-producing Salmonella spp. in Kuwait and the United Arab Emirates. J Med Microbiol. 2008;57:881–6.
- Singhal S, Mathur T, Khan S, Upadhay DJ, Chugh S, Gaind R, Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol. 2005;23:120–4.
- Mabilat C, Goussard S. PCR detection and identification of genes for extended spectrum β-lactamases. In: Persiang DH, Smith TF, Tenover FC, White TJ, editors. Diagnostic molecular microbiology: principles and applications. Washington: American Society for Microbiology; 1993. p. 553–9.
- Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol. 2002;40:2153–62.
- Frankel G, Newton SM, Schoolnik GK, Stocker BA. Unique sequences in region VI of the flagellin gene of Salmonella typhi. Mol Microbiol. 1989;3:1379–83.
- Bidet P, Burghoffer B, Gautier V, Brahimi N, Mariani-Kurkdjian P, El-Ghoneimi A, In vivo transfer of plasmid-encoded ACC-1 ampC from Klebsiella pneumoniae to Escherichia coli in an infant and selection of impermeability to imipenem in K. pneumoniae. Antimicrob Agents Chemother. 2005;49:3562–5.
- Bauernfeind A, Schneider I, Jungwirth R, Sahly H, Ullmann U. A novel type of AmpC β-lactamase, ACC-1, produced by a Klebsiella pneumoniae strain causing nosocomial pneumonia. Antimicrob Agents Chemother. 1999;43:1924–31.
Suggested citation for this article: Gokul BN, Menezes GA, Harish BN. ACC-1 β-lactamase–producing Salmonella enterica serovar Typhi, India [letter]. Emerg Infect Dis [serial on the Internet]. 2010 Jul [date cited]. http://wwwnc.cdc.gov/eid/article/16/7/09-1643
Please use the form below to submit correspondence to the authors or contact them at the following address:
Belgode N. Harish, Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: March 02, 2011
- Page last updated: March 02, 2011
- Page last reviewed: March 02, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)